Mononuclear phagocytes and their use to promote axonal regeneration
CA 2283891 A1 · Owner: Spiegler, Orly · Inventors: Spiegler, Orly; Eisenbach-Schwartz, Michal
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions are disclosed for the use of allogeneic mononuclear phagocytes to promote axonal regeneration in the central nervous system of a mammal. In one embodiment, allogeneic mononuclear phagocytes are administered into the CNS at or near a site of injury or disease and the mammal is treated with at least one anti-inflammatory agent. In another embodiment allogeneic , mononuclear phagocytes are administered into the CNS at or near a site of injury or disease and one or more enumerated adjuvant factors (e.g. aFGF) are administered to the CNS; anti-inflammatory therapy of the mammal may optionally be added. In a further embodiment allogeneic mononuclear , phagocytes …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 13, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 13, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 13, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.